Silo Pharma, Inc. (SILO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25K 50K 75K Q1 '21: 47.4K Q2 '21: 68.1K Q1 '22: 18K Q2 '22: 18K Q3 '22: 18K Q4 '22: 18K Q1 '23: 18K Q2 '23: 18K Q3 '23: 18K Q4 '23: 18K Q1 '24: 18K Q2 '24: 18K Q3 '24: 18K Q4 '24: 18K Q1 '25: 18K Q2 '25: 18K Q3 '25: 18K Q4 '25: 18K Q1 '26: 18K Q2 '26: 0 Q2 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

-6K 0 6K 12K 18K Q3 '21: 16.6K Q4 '21: 16.6K Q1 '22: 16.6K Q2 '22: 16.6K Q3 '22: 16.6K Q4 '22: 16.6K Q1 '23: 16.6K Q2 '23: 16.6K Q3 '23: 16.6K Q4 '23: 16.6K Q1 '24: 16.6K Q2 '24: 16.6K Q3 '24: 16.6K Q4 '24: 16.6K Q1 '25: 16.6K Q2 '25: 16.6K Q3 '25: -2.7K Q4 '25: -2.7K Q1 '26: -2.7K Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q3 '21: -463.9K Q4 '21: -942.4K Q1 '22: -527.3K Q2 '22: -494.3K Q3 '22: -949.2K Q4 '22: -1.7M Q1 '23: -803.5K Q2 '23: -1.1M Q3 '23: -773.4K Q4 '23: -1.2M Q1 '24: -879.5K Q2 '24: -1M Q3 '24: -1M Q4 '24: -1.8M Q1 '25: -1.1M Q2 '25: -1.2M Q3 '25: -1.2M Q4 '25: -786.5K Q1 '26: -1.6M Q2 '26: -928.9K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-2.5M 0 2.5M 5M 7.5M Q3 '21: 6.4M Q4 '21: -1.1M Q1 '22: -604.1K Q2 '22: -658.4K Q3 '22: -983.2K Q4 '22: -1.7M Q1 '23: -906.4K Q2 '23: -1M Q3 '23: -660.2K Q4 '23: -1.1M Q1 '24: -801.7K Q2 '24: -931.8K Q3 '24: -928.8K Q4 '24: -1.7M Q1 '25: -1M Q2 '25: -1.2M Q3 '25: -1.1M Q4 '25: -881.5K Q1 '26: -1.6M Q2 '26: -832.8K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 8K 16K 24K Q3 '21: 1.5K Q4 '21: 1.5K Q1 '22: 1.5K Q2 '22: 1.5K Q3 '22: 1.5K Q4 '22: 1.5K Q1 '23: 1.5K Q2 '23: 1.5K Q3 '23: 1.5K Q4 '23: 1.5K Q1 '24: 1.5K Q2 '24: 1.5K Q3 '24: 1.5K Q4 '24: 1.5K Q1 '25: 1.5K Q2 '25: 1.5K Q3 '25: 20.7K Q4 '25: 20.7K Q1 '26: 20.7K Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q3 '21: -663.1K Q4 '21: -773.9K Q1 '22: -789.2K Q2 '22: -400.1K Q3 '22: -1.4M Q4 '22: -886K Q1 '23: -692.7K Q2 '23: -550K Q3 '23: -1.1M Q4 '23: -910K Q1 '24: -838.2K Q2 '24: -731.8K Q3 '24: -1.3M Q4 '24: -917.4K Q1 '25: -1.6M Q2 '25: -1.3M Q3 '25: -955.5K Q4 '25: -780.3K Q1 '26: -822.6K Q2 '26: -781.9K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '19: 23.4M Q3 '19: 23.5M Q3 '20: 84.4M Q1 '21: 85.1M Q2 '21: 96.9M Q3 '21: 2M Q1 '22: 2M Q2 '22: 2M Q3 '22: 2M Q1 '23: 3.2M Q2 '23: 3.2M Q3 '23: 3.1M Q1 '24: 2.9M Q2 '24: 3.1M Q3 '24: 4.3M Q1 '25: 4.5M Q2 '25: 418.6K Q3 '25: 9.3M Q1 '26: 13.7M Q2 '26: 1.1M Q3 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '19: -0.04 Q1 '20: -0.04 Q2 '20: -0.07 Q3 '20: -0.07 Q4 '20: -0.07 Q1 '21: -0.06 Q2 '21: -0.02 Q3 '21: 3.15 Q4 '21: 0.04 Q1 '22: 0.04 Q2 '22: 0.04 Q3 '22: -3.61 Q4 '23: -1.20 Q1 '24: -1.19 Q2 '24: -1.18 Q3 '24: -1.19 Q4 '24: -1.22 Q1 '25: -1.17 Q2 '25: -3.74 Q3 '25: -3.64 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.